Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07562152 Albumin-Bound Paclitaxel Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07562152 clinical trial report covering Albumin-Bound Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07560306 [64Cu]FBP8 Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07560306 clinical trial report covering [64Cu]FBP8, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07565428 Aripiprazole Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07565428 clinical trial report covering Aripiprazole, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07566052 Setidegrasib KRAS G12D mutation Non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07566052 clinical trial report covering Setidegrasib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07566195 Tozorakimab Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07566195 clinical trial report covering Tozorakimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07566156 Enfortumab Vedotin-ejfv Muscle Invasive Bladder Urothelial Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07566156 clinical trial report covering Enfortumab Vedotin-ejfv, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564414 Semaglutide/Cagrilintide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07564414 clinical trial report covering Semaglutide/Cagrilintide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07563881 RAP-219 Seizures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07563881 clinical trial report covering RAP-219, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Mogamulizumab Biologics Sequence Review Report 2026: CCR4 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mogamulizumab, an antibody targeting CCR4.
Latest Hotspot
8 min read
NCT07565870 Methadone Hydrochloride Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07565870 clinical trial report covering Methadone Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564141 Rinatabart Sesutecan Platinum-Sensitive Ovarian Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07564141 clinical trial report covering Rinatabart Sesutecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Alemtuzumab Biologics Sequence Review Report 2026: CD52 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alemtuzumab, an antibody targeting CD52.